Costimulatory wars: The tumor menace

Advances in our understanding of T cell costimulatory molecules have provided a vast array of novel approaches to tumor immunotherapy. In the past year, combinatorial immunotherapy based on earlier studies of CTLA-4 blockade, the identification of novel B7-family members, the modulation of CD40 to reverse tolerance to tumor-associated antigens and the use of OX40 to enhance antitumor responses of CD4⁺ T cells have all contributed to the development of more-powerful immunomodulatory cancer therapies. (C) 2000 Elsevier Science Ltd.